Pinned post
Finally out! Check out this paper @LeukemiaJnl
➡️➡️intensive chemotherapy for high-risk (HR) ALL patients in the NOPHO ALL2008 study 🥳
* Minimized HR allocation ➡️18% of the entire cohort
* Of 314 HR patients (age 1–45), the 5-y EFS 64% (OS 70%)
* B-ALL patients (N=185) had a 5-y EFS of 68% (RR 24%), which was higher than the 59% EFS (RR 23%) for T-ALL (N=129)
* Treatment-related mortality in first complete remission (DCR1) higher for T-ALL at 17%, compared to 8% for BCP-ALL
* Patients stratified by HR genetics (KMT2A, hypo) had EFS of 74%: outcomes limited by treatment toxicity (RR 13%)
* Patients stratified due to inadequate treatment response had an EFS of 58% and RR of 29%
* High WBC counts and adult age (≥18 years) were confirmed as adverse prognostic markers
‼️Results implemented in ongoing ALLTogether trial ➡️➡️ aim to minimize use of the most intensive blocks. 💉📈💡
Thanks to @AtteNikkila and all colleagues 👏👏👏
➡️➡️intensive chemotherapy for high-risk (HR) ALL patients in the NOPHO ALL2008 study 🥳
* Minimized HR allocation ➡️18% of the entire cohort
* Of 314 HR patients (age 1–45), the 5-y EFS 64% (OS 70%)
* B-ALL patients (N=185) had a 5-y EFS of 68% (RR 24%), which was higher than the 59% EFS (RR 23%) for T-ALL (N=129)
* Treatment-related mortality in first complete remission (DCR1) higher for T-ALL at 17%, compared to 8% for BCP-ALL
* Patients stratified by HR genetics (KMT2A, hypo) had EFS of 74%: outcomes limited by treatment toxicity (RR 13%)
* Patients stratified due to inadequate treatment response had an EFS of 58% and RR of 29%
* High WBC counts and adult age (≥18 years) were confirmed as adverse prognostic markers
‼️Results implemented in ongoing ALLTogether trial ➡️➡️ aim to minimize use of the most intensive blocks. 💉📈💡
Thanks to @AtteNikkila and all colleagues 👏👏👏